Preclinical proof-of-concept studies, including ex vivo enzymatic conversion of blood type A human donor lungs to universal blood type for transplantation, have been published and support the feasibility of ABO antigen conversion in organs and blood products[2][3]. No clinical trials have yet been reported; the company is described as preclinical-stage[2][3][5][7].
University of British Columbia (Michael Smith Laboratories) – academic founding and ongoing collaboration on enzyme discovery and organ perfusion studies[2][3][4].Canadian Glycomics Network (GlycoNet) – non-dilutive funding and commercialization support for glycomics-based technology[2][6][8].Genome British Columbia – non-dilutive funding support[2].NRC-IRAP – non-dilutive funding support[2].MITACS – non-dilutive funding support[2].US Air Force (grant funding through UBC collaborators for related research)[2].
Beyond the preview
Go deeper on Avivo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
Trial phase
Status
Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
Partners
Deal terms
Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
Funding rounds
Investors
Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
Peer companies
Targets
Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
Platforms
Patents
Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
Company news
Sources
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avivo.